Flotek Industries heads into the post-print session with a mixed Q1 report: revenue came in strong but the bottom line fell short, leaving the market to decide which number matters more.
Q1 sales hit $70.1 million, well ahead of the $61.1 million consensus. EPS came in at $0.12, a penny below the $0.14 estimate. Full-year revenue guidance of $270–$290 million topped the $266 million street estimate — the top-line story, at least, remains intact. FY2025 showed the same pattern at a bigger scale: full-year revenue of $237 million was up 27% year-on-year and net income tripled to $30.5 million, so management has some credibility when it sets optimistic targets.
The stock has drifted only fractionally this week, down less than 0.6%, closing Tuesday at $16.86. That relative calm sits against a month that has been kinder — up 5.2% over 30 days. Correlated peers have been more volatile. IPI gained 6.9% on the week, and ASPN surged 14.7%, which suggests broader specialty-chemicals appetite has been supportive even as FTK treaded water into earnings.
Short positioning is the most consequential piece of the picture right now. Short interest is running at roughly 7.5% of the free float — a level that means there is a meaningful population of sellers who need to be right on the earnings thesis. That figure has climbed about 10% over the past month, peaking in late April near 16.4% on one float-adjusted calculation, before easing modestly this week. The ORTEX short score is 76.2, a high reading that flags sustained short-side conviction rather than a fleeting trade. Availability in the lending market is relatively comfortable — roughly half the lending pool remains undeployed — so there is no mechanical squeeze pressure from a supply-of-borrows standpoint. Cost to borrow is just 0.62%, having drifted lower over the past month from above 0.9% in late March, meaning the carry cost of holding a short is low enough not to force anyone out.
Options tell the opposite story to the shorts. The put/call ratio is 0.21 — well below its 20-day average of 0.27 and near the lower end of its 52-week range of 0.08 to 0.52. That low ratio reflects call dominance: options traders were leaning bullish into the print. The divergence between elevated short interest and call-heavy options flow was the defining tension heading into the May 6 earnings call, and how the market reconciles those two positions in the sessions ahead is the key dynamic to watch.
Analyst coverage remains thin and somewhat stale. Northland Capital Markets reiterated Outperform with a $20 target at year-end 2025, up from an earlier Market Perform initiation at $16 in mid-2025. Roth MKM carries a Buy with a $8 target — a figure that appears dated and inconsistent with current trading levels near $17, so that data point should be treated with caution. The mean price target of $21.25, if taken at face value, implies roughly 26% upside from the Tuesday close, but the coverage universe is narrow and the most recent formal update is from mid-March 2026. The EV/EBITDA multiple is 11.1x, essentially flat on the week; the P/E is 20.9x. Neither is stretched for a specialty-chemicals name with the revenue trajectory Flotek has shown.
Ownership is dominated by ProFrac Holding Corp., which holds 58% of shares outstanding and added 6 million shares as recently as March 2026 — an anchor holder with an industrial rationale that structurally constrains the free float and amplifies any short-term positioning moves. On the insider side, CEO Ryan Ezell and CFO James Clement both sold small amounts in February alongside equity award grants, routine compensation events with trade significance scores of just 1 out of 10. No material insider buying or selling stands out as an independent signal.
With the Q1 call now complete, the next focal point is the Louisiana Energy Conference at the end of May — a venue where management can either reinforce or refine the full-year revenue guidance range that now sits ahead of prior consensus.
See the live data behind this article on ORTEX.
Open FTK on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
